Fudan tumor cross fusion adds another "weapon": completing the first PRLT clinical trial with precise targeting of prostate cancer | discipline | first case

Release time:Apr 14, 2024 12:04 PM

Cancer treatment "weapon": Fudan University Affiliated Cancer Hospital recently completed the first PRLT clinical trial patient administration through interdisciplinary integration, bringing more treatment opportunities for patients with refractory prostate cancer.

Patient Zhao, 67 years old, was diagnosed with prostate cancer five years ago. After undergoing new endocrine therapy, chemotherapy, and PARP inhibitors, his condition has progressed again. After a multidisciplinary team led by Professor Ye Dingwei from the Department of Oncology and Urology at Fudan University, it was recommended to carry out PRLT therapy. The so-called PRLT is prostate specific membrane antigen receptor radioactive therapy. Professor Song Shaoli, Director of Nuclear Medicine, introduced that prostate cancer lesions generally exhibit high expression of PSMA. Introducing the "nuclear missile" -177 lutetium PSMA into the body can specifically target tumor cells for precise strikes, and can play a dual role in biological therapy and tumor internal irradiation to kill tumors.

Based on PSMA precise imaging and multidisciplinary comprehensive treatment, the five-year survival rate of prostate cancer in Fudan City far exceeds the domestic average level. The use of 177 lutetium PSMA in this treatment has become a dawn of life for advanced refractory patients. The reporter learned that in recent years, the Department of Nuclear Medicine has continued to explore prostate cancer. Experts explain that 87% of metastatic prostate cancer cells have high expression of PSMA, which is a type II transmembrane receptor located in prostate cancer cells and has become an ideal target. By labeling the PSMA ligand with 177Lu, 177lutetium-PSMA-617 can be formed, which can accurately identify high expression PSMA prostate cancer lesions and has the advantages of strong killing power and minimal damage in treatment.

Previous large-scale studies abroad have confirmed that 177 lutetium PSMA can effectively prolong the overall survival of prostate cancer patients by 4 months, prolong the progression free imaging by 5.3 months, and reduce PSA levels by more than 50% in 46% of patients, with overall good tolerability. However, experts also remind that this therapy is not suitable for everyone, and only patients with PSMA positive metastatic lesions are eligible for treatment indications.

It is reported that Fudan Tumor is the earliest unit in China to carry out PSMA imaging, and has independently developed 99mTc PSMA SPECT/CT imaging probes and obtained intellectual property rights. After the opening of the nuclide ward, clinical trials involving nuclide diagnosis and treatment in various phases will be carried out. Currently, the three leading nuclide treatment projects for prostate cancer are being carried out as scheduled. Professor Wu Jiong, Executive Vice President, finally stated that the collaboration between the Department of Urology and the Department of Nuclear Medicine will provide patients with new treatment options. In the future, the hospital will continue to promote interdisciplinary integration and solve more clinical bottleneck problems.

Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer

Immunotherapy has been proven to achieve significant therapeutic effects in various solid tumors. However, for pancreatic cancer, known as the "king of cancer", immunotherapy has been ineffective. On August 4, Professor Yu Xianjun, Dean of the Cancer Hospital Affiliated to Fudan University, and Shi Si, Associate Professor of Pancreatic Surgery released a research achievement, which first found the key role of cysteine rich protein 1 in shaping the immunosuppressive microenvironment of pancreatic cancer, filled the gap in the research field of immunosuppressive microenvironment of pancreatic cancer, and provided a theoretical basis for precise immunotherapy of pancreatic cancer patients. Ductal adenocarcinoma of the pancreas is the main type of pancreatic cancer, accounting for about 90% of all pancreatic cancer. Due to its high malignancy and poor treatment effectiveness, pancreatic ductal adenocarcinoma has always been one of the most malignant tumors. In recent years, the level of surgical techniques and comprehensive treatment has been achieved

A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare
A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare

A 14-year-old girl has been experiencing symptoms such as protruding pupils, incomplete eye closure, corneal injury, restricted eye movement, and overall fatigue for several years. The physical discomfort and facial abnormalities caused by eye diseases have made her increasingly reticent, and her temperament is vastly different from before. At the Ophthalmology Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the pupil has been diagnosed with a rare thyroid ophthalmopathy combined with myasthenia gravis, which requires prompt treatment. However, considering the young age of the pupil, conventional hormone and radiation therapy cannot be used. Therefore, Zhou Huifang, Deputy Director of Ophthalmology and thyroid ophthalmology expert, has developed a targeted drug combined with surgical treatment plan for it, and targeted drug treatment will be performed first. Three months ago, I was hospitalized for one week with mydriasis and received intravenous targeted drug treatment. Afterwards, I went home for observation and followed up on time

The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease
The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease

According to the Statistics of Chinese Dry Eye Expert Consensus, the incidence rate of dry eye in China is about 21%~30%, and it is estimated that there are at least 300 million patients nationwide. The Dry Eye Diagnosis and Treatment Studio of Shanghai Eye Disease Prevention and Treatment Center was officially launched today. In the future, the studio will continuously improve the dry eye diagnosis and treatment standards, and form standardized diagnosis and treatment concepts and service models. Suitable technologies will be promoted to the community, allowing residents to enjoy convenient dry eye diagnosis and treatment services at their doorstep. Executive Dean and Party Secretary Gao Wei stated that this is also one of the livelihood service measures recently launched by the hospital around high-quality development and meeting the needs of the people. It is reported that dry eye syndrome is a chronic ocular surface disease caused by multiple factors. The instability of the tear film or imbalance of the ocular surface microenvironment caused by abnormal quality, quantity, and dynamics of tears can be accompanied by ocular surface inflammatory reactions, tissue damage, and nerve abnormalities, resulting in various discomforts in the eyes

The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice
The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice

The International Dental Implant Consensus Report, jointly written by the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine and renowned universities in the field of dentistry such as Harvard University, University of Zurich, University of Gothenburg, Columbia University, and University of Frankfurt, has recently been jointly published in top journals in the field of dentistry, including Clinical Periodontology and Clinical Dental Implant Research. This consensus has for the first time established an internationally unified core set of indicators for evaluating the clinical effectiveness of dental implants, covering the five key areas of the field of dental implants. It is of milestone significance for carrying out standardized clinical diagnosis, treatment, and research on dental implants. The core evaluation indicators determined by this consensus will become an important benchmark for scholars in the field of dental implants worldwide to conduct high-quality research. The consensus is composed of 8 top international experts in the field of oral implantation

Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases
Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases

Recently, Catherine, a British girl born in the 1990s, received autologous peripheral blood hematopoietic stem cell transfusion at the Cancer Center of Shanghai Jiahui International Hospital, and was successfully discharged from the warehouse. She is now on her way back to China after being discharged from the hospital. She is also the first patient at Shanghai Jiahui International Hospital to complete relevant treatments. In 2019, Catherine was diagnosed with Hodgkin's lymphoma in the UK, and after treatment, the disease completely improved. During her work and life in China in 2021, she went to seek medical attention due to multiple enlarged lymph nodes. Pathological biopsy confirmed a recurrence of Hodgkin's lymphoma, and through combined targeted drug treatment, her condition was temporarily under control. Last year in the second half of the year, when the disease recurred, the girl began to use immunotherapy combined with targeted drugs for treatment. Expert evaluation suggests that for young patients with hematological tumors, the risk of recurrence is high and treatment difficulty is increasing in the future. Autologous hematopoietic stem cell therapy is recommended